Show/Hide Menu

History
of MorphoSys

You are here

MorphoSys was founded in Martinsried near Munich in 1992. The founders included Dr. Simon Moroney, today’s CEO of the Company and Prof. Dr. Andreas Plückthun. Today, MorphoSys is one of the world’s leading biotechnology companies in the area of fully human antibodies.

1992

Company founded in Martinsried/Munich, Germany

1997

First commercial partnership with Pharmacia-Upjohn

Move to the Innovation and Start-up Center for Biotechnology (IZB) Martinsried

2002

MorphoSys achieves a settlement of the CAT patent dispute

Dr. Simon E. Moroney receives the Bundesverdienstkreuz am Bande (Cross of the Order of Merit of the Federal Republic of Germany)

2004

Start of a strategic partnership with Novartis

Presentation of the new research antibodies division, Antibodies by Design

Inclusion in the technology index TecDAX

MorphoSys achieves break even

2005

The first HuCAL antibodies used in clinics

Acquisition of Biogenesis Group strengthens the research segment

First partnership with a Japanese pharmaceutical group

2006

Acquisition of Serotec Group further strengthens the research segment

HuCAL antibodies to combat Alzheimer’s disease are used in clinics

2007

MorphoSys announces development of new antibody platform technology

MorphoSys and Novartis forge one of the industry’s largest pharma-biotech R&D collaborations

2008

First proprietary therapeutic antibody MOR103 enters clinical trials

MorphoSys unveils new antibody library, HuCAL PLATINUM 

First HuCAL antibody enters phase 2 clinical trials

2009

MorphoSys signs first infectious disease alliance with Daiichi-Sankyo

2010

First proprietary therapeutic antibody in a patient setting

First in-licensing of a clinical antibody from Xencor

Aquisition of Sloning BioTechnology

MorphoSys presents new antibody technology arYla

2011

MOR202 enters clinical development

MorphoSys presents new antibody technology Ylanthia

MorphoSys signs first industrial biotechnology alliance with Novozymes

2012

MorphoSys announces positive clinical data for MOR103 in RA and MOR208 in CLL

With gantenerumab from Roche, the first partnered antibody program reaches late stage development

MorphoSys celebrates its 20th anniversary

MorphoSys signs first Ylanthia-based therapeutic partnership

2015

MorphoSys and Emergent BioSolutions announce the beginning of a joint clinical phase 1 trial of MOR209/ES414 in patients with metastatic, castration-resistant prostate cancer (mCRPC).

Awards & Recognition

Mediscience Award 2013

Capital Investor Relations Preis 2010

Technology Pioneer 2009

Land der Ideen 2006